25 Years of Trust, Quality, and Health: SFI Health™ celebrates Equazen® milestone, the brand of food supplements developed to support cognitive needs

Contributed by: Business Wire

Logo

Images

Discover Equazen® comprehensive range: multiple pharmaceutical formats and sizes to support the cognitive health of infants, children and teenagers. For more info visit www.equazen.com

Business Wire embedded0

Tags

General Health

Vitamins/Supplements

Health

Fitness & Nutrition

Pharmaceutical

Equazen

More Like This

Equazen® continues to set the benchmark for excellence at every step of the value chain

Equazen® Reaffirms Its Commitment to Uncompromising Quality and Sustainability in Omegas Supplements

Discover Equazen®, a science-based food supplement designed and studied to help nourish, enhance, and support the human brain’s potential across all life stages. (Graphic: Business Wire)

SFI Health™ EMEA Announces the Launch in Portugal of Equazen® Food Supplements, the Brand Developed to Support Cognitive Needs

Business Wire associated0

Empowering Local Industry: SFI Health™ EMEA Commits to South African Packing Operations

FutureCeuticals Announces Publication of Groundbreaking Study on CognatiQ®'s Same-Day Cognitive Benefits

PR Newswire associated0

INTRODUCING JUICE PLUS+ LUMINATE: ONE OF THE FIRST, RAPID ACTING, PLANT-BASED PRODUCTS DESIGNED TO SUPPORT MENTAL CLARITY, FOCUS, AND ENERGY

Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of Medicines & Healthcare

The recently launched VitaZhi range includes two formulas specifically designed to combat the lingering effects of the COVID-19 virus and its associated vaccinations, in addition to formulas designed to support anxiety, aid sleep and detox from unwanted parasites (Photo: Business Wire)

Irish Healthcare Company AstroZhi Unveils Groundbreaking Dietary Supplements for the Management of Long-COVID Syndrome in the Irish, UK and European Markets

EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round